NASDAQ:EVGN Evogene (EVGN) Stock Price, News & Analysis $1.36 0.00 (0.00%) Closing price 07/3/2025 03:50 PM EasternExtended Trading$1.36 -0.01 (-0.37%) As of 07/3/2025 04:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Evogene Stock (NASDAQ:EVGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Evogene alerts:Sign Up Key Stats Today's Range$1.34▼$1.3850-Day Range$1.10▼$2.2652-Week Range$0.95▼$6.80Volume44,787 shsAverage Volume625,226 shsMarket Capitalization$7.30 millionP/E RatioN/ADividend YieldN/APrice Target$3.50Consensus RatingBuy Company Overview Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel. Read More Evogene Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks30th Percentile Overall ScoreEVGN MarketRank™: Evogene scored higher than 30% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingEvogene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEvogene has only been the subject of 1 research reports in the past 90 days.Read more about Evogene's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Evogene is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Evogene is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEvogene has a P/B Ratio of 0.49. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Evogene's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.54% of the float of Evogene has been sold short.Short Interest Ratio / Days to CoverEvogene has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Evogene has recently increased by 320.44%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEvogene does not currently pay a dividend.Dividend GrowthEvogene does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.54% of the float of Evogene has been sold short.Short Interest Ratio / Days to CoverEvogene has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Evogene has recently increased by 320.44%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News SentimentN/A Search Interest8 people have searched for EVGN on MarketBeat in the last 30 days. This is an increase of 700% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Evogene insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.40% of the stock of Evogene is held by insiders.Percentage Held by InstitutionsOnly 10.40% of the stock of Evogene is held by institutions.Read more about Evogene's insider trading history. Receive EVGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evogene and its competitors with MarketBeat's FREE daily newsletter. Email Address EVGN Stock News HeadlinesEvogene Announces Completion of First-In-Class Foundation Model for Generative Molecule Design, Developed in Collaboration with Google CloudJune 10, 2025 | prnewswire.comEvogene Ltd. Earnings Call: Balancing Growth and ChallengesMay 22, 2025 | tipranks.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history. | Paradigm Press (Ad)Earnings call transcript: Evogene Reports Narrower Loss in Q1 2025May 22, 2025 | uk.investing.comEvogene Ltd (EVGN) Q1 2025 Earnings Call Highlights: Strategic Expense Reductions and Promising ...May 22, 2025 | finance.yahoo.comEvogene Ltd. Reports Q1 2025 Financial ResultsMay 21, 2025 | tipranks.comEvogene Ltd. (EVGN) Q1 2025 Earnings Call TranscriptMay 21, 2025 | seekingalpha.comEvogene Reports First Quarter 2025 Financial ResultsMay 21, 2025 | prnewswire.comSee More Headlines EVGN Stock Analysis - Frequently Asked Questions How have EVGN shares performed this year? Evogene's stock was trading at $1.87 at the start of the year. Since then, EVGN shares have decreased by 27.3% and is now trading at $1.36. How were Evogene's earnings last quarter? Evogene Ltd. (NASDAQ:EVGN) released its earnings results on Wednesday, May, 21st. The biotechnology company reported ($0.38) earnings per share for the quarter, beating analysts' consensus estimates of ($0.50) by $0.12. The biotechnology company had revenue of $2.44 million for the quarter, compared to analysts' expectations of $4.42 million. Evogene had a negative net margin of 224.82% and a negative trailing twelve-month return on equity of 102.40%. Read the conference call transcript. When did Evogene's stock split? Evogene's stock reverse split before market open on Thursday, July 25th 2024.The 1-10 reverse split was announced on Tuesday, July 23rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 24th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Evogene? Shares of EVGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Evogene own? Based on aggregate information from My MarketBeat watchlists, some other companies that Evogene investors own include Tesla (TSLA), NIO (NIO), NVIDIA (NVDA), Plug Power (PLUG), Riot Platforms (RIOT) and AquaBounty Technologies (AQB). Company Calendar Last Earnings5/21/2025Today7/03/2025Next Earnings (Estimated)8/20/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryChemicals Current SymbolNASDAQ:EVGN CIK1574565 Webwww.evogene.com Phone(728) 931-1900Fax972-8946-6724Employees140Year FoundedN/APrice Target and Rating Average Stock Price Target$3.50 High Stock Price Target$3.50 Low Stock Price Target$3.50 Potential Upside/Downside+157.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($2.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$16.49 million Net Margins-224.82% Pretax Margin-254.09% Return on Equity-102.40% Return on Assets-39.19% Debt Debt-to-Equity RatioN/A Current Ratio1.06 Quick Ratio0.92 Sales & Book Value Annual Sales$8.51 million Price / Sales0.86 Cash FlowN/A Price / Cash FlowN/A Book Value$2.77 per share Price / Book0.49Miscellaneous Outstanding Shares5,370,000Free Float4,968,000Market Cap$7.30 million OptionableOptionable Beta1.58 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free Report This page (NASDAQ:EVGN) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evogene Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evogene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.